Retirement Planning Co of New England Inc. Sells 1,016 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Retirement Planning Co of New England Inc. reduced its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 21,427 shares of the specialty pharmaceutical company’s stock after selling 1,016 shares during the quarter. Retirement Planning Co of New England Inc.’s holdings in Supernus Pharmaceuticals were worth $775,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of SUPN. Principal Financial Group Inc. raised its holdings in Supernus Pharmaceuticals by 5.4% in the 3rd quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company’s stock worth $8,899,000 after purchasing an additional 14,566 shares during the period. State of New Jersey Common Pension Fund D bought a new position in Supernus Pharmaceuticals in the 3rd quarter worth $1,774,000. Victory Capital Management Inc. raised its holdings in Supernus Pharmaceuticals by 1.1% in the 3rd quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock worth $23,163,000 after purchasing an additional 7,833 shares during the period. Natixis Advisors LLC raised its holdings in Supernus Pharmaceuticals by 14.9% in the 3rd quarter. Natixis Advisors LLC now owns 39,318 shares of the specialty pharmaceutical company’s stock worth $1,226,000 after purchasing an additional 5,113 shares during the period. Finally, Quest Partners LLC bought a new stake in Supernus Pharmaceuticals during the third quarter valued at about $241,000.

Supernus Pharmaceuticals Stock Up 2.9 %

NASDAQ:SUPN opened at $32.16 on Tuesday. The business’s 50-day simple moving average is $36.13 and its two-hundred day simple moving average is $35.15. The stock has a market cap of $1.79 billion, a PE ratio of 30.06 and a beta of 0.83. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on SUPN shares. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Insider Activity

In related news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares in the company, valued at $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock worth $440,263 over the last 90 days. Corporate insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.